Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Immune-mediated colitis after immune checkpoint inhibitor therapy | Synapse

October 30, 2024Open Access

Ver artículo completo

Immune-mediated colitis after immune checkpoint inhibitor therapy

SGSophie GieslerUniversity of Freiburg RRR. Kirk RiemerStanford University TLTheresa LowinusUniversity of Freiburg

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

antibodies. Given that systemic immunosuppression might impair antitumor immune responses, novel therapeutic approaches are urgently needed.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Giesler et al. (Wed,) studied this question.

synapsesocial.com/papers/6a0cc5369d761985b14a46dc https://doi.org/https://doi.org/10.1016/j.molmed.2024.09.009

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade2017 · 199 citations
2Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis2016 · 969 citations
3Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors2018 · 184 citations
4Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies2021 · 33 citations
5Immune mediated colitis: a surgical perspective2023 · 8 citations